Cancer Research: The Lessons to Learn from COVID-19.
Chris BaileyJames R M BlackCharles SwantonPublished in: Cancer discovery (2020)
The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.